{"id":"NCT00165646","sponsor":"Eisai Co., Ltd.","briefTitle":"A Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease","officialTitle":"A Double-Blind, Placebo-Controlled, Comparative Study on the Efficacy and Safety of E3810 in Patients With Non-erosive Gastroesophageal Reflux Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2005-10","completion":"2005-10","firstPosted":"2005-09-14","resultsPosted":"2011-06-17","lastUpdate":"2011-07-18"},"enrollment":288,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-erosive Gastroesophageal Reflux Disease"],"interventions":[{"type":"DRUG","name":"E3810","otherNames":[]},{"type":"DRUG","name":"E3810","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal reflux disease in a multicenter, randomized, double-blind, comparative study.","primaryOutcome":{"measure":"Percentage of Participants With Complete Relief of Heartburn at Final Evaluation","timeFrame":"4 weeks","effectByArm":[{"arm":"Placebo","deltaMin":20.9,"sd":null},{"arm":"E3810 5 mg","deltaMin":34.4,"sd":null},{"arm":"E3810 10 mg","deltaMin":43.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":91},"commonTop":["Nasopharyngitis","Abdominal distension","Diarrhoea","Upper respiratory tract inflammation","Nausea"]}}